Researchers from the John Hopkins University School of Medicine in America have identified potential biomarkers that may predict whether patients with kidney cancer are likely to respond to treatment with immunotherapy drugs that target the PD-1/PD-L1 pathway, such as nivolumab. Evidence from some studies suggests that renal cell carcinomas (RCCs) positive for PD-L1 are more likely to respond to PD-1 inhibitors compared to those negative for PD-L1. However, the researchers noted that not all PD-L1-positive RCCs respond to these immunotherapies.
Read more about this research in these two articles:
Biomarkers May Identify Which Patients With Renal Cell Carcinoma Will Benefit From Nivolumab
Gene expression profile may ID renal cell carcinoma patients unlikely to benefit from nivolumab